Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy

Overview

The purpose of this study is to 1. Early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools 2. get gene repertoire of Chinese 3. Build a cerebral amyloid angiopathy (CAA) prospective cohorts, observing the disease history, and exploring prognostic factors of hemorrhage in CAA patients

Full Title of Study: “A Research of the Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2016

Detailed Description

We recruited consecutive patients with intracerebral hemorrhage(ICH). Clinical data and the results of laboratory tests and CT will be assessed and recorded. All the subjects will get gene tests including many genes related with Aβ and small vessel disease (Next-generation sequencing and target enrichment system) . The result of the MRI Scans including cerebral microbleeds(CMBs)、Cortical superficial siderosis(cSS), white matter change(WMC) and enlarged perivascular spaces (EPVS) will be assessed using scales. Ocular fundus exams such as funduscopy and imaging will be used to assess multiple dot and blot hemorrhages and microaneurysms by ophthalmologist. Mini-mental state examination(MMSE) will be used to assess the cognitive function. Patients who need operation on the hematoma for the treatment will accept a brain tissue pathological exams According to this, a prospective cohort of CAA patients based on clinical manifestation, imaging, gene and histology will be built, and diagnostic tools such as gene and MRI results, etc will be explored. And we will get gene repertoire of Chinese patient with ICH. Then, the subjects will be followed up on 30-day, 3-month, 6-month, and 1-year.The patients' clinical outcome will be assessed , and the results of laboratory tests and therapy will be recorded. Prognostic factors of patients with CAA related ICH will be explored.

Clinical Trial Outcome Measures

Primary Measures

  • apolipoprotein E gene polymorphism
    • Time Frame: baseline

Secondary Measures

  • CMBs were evaluated using the Microbleed Anatomical Rating Scale (MARS)
    • Time Frame: baseline
  • a composite outcome including multiple dot and blot hemorrhages and microaneurysms of the fundus
    • Time Frame: baseline
  • recurrence of cerebral hemorrhage
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

①diagnosed wiht spontaneous cerebral hemorrhage after the head CT. ② the patients and their family members agreed to participate in this study. Exclusion Criteria:

①cerebral hemorrhage caused by traumatic, cerebral infarction, tumor and arteriovenous malformation. ②patients who can not provide reliable information or are considered unsuitable for the study.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University Third Hospital
  • Collaborator
    • Beijing Municipal Science & Technology Commission
  • Provider of Information About this Clinical Study
    • Principal Investigator: Fan Dongsheng, Chairman of the department of neurolog of Peking University Third Hospital – Peking University Third Hospital
  • Overall Official(s)
    • Dongsheng Fan, doctor, Principal Investigator, Peking University Third Hospital
  • Overall Contact(s)
    • Dongsheng Fan, doctor, +861082266699, dsfan@sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.